Abiopharma

🔍 Maduck Sean (Executive)

Company: CORCEPT THERAPEUTICS INC (CORT)

Report Date: 2025-09-02

Detailed Transactions and Holdings:

• Acquired 20,000 shares of Common Stock at $5.05 per share (Direct)
  Date: 2025-09-02 | Code: M | equity_swap_involved: false | shares_owned_after: 27,681.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 15,070 shares of Common Stock at $70.3787 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: false | shares_owned_after: 12,611.00 | transaction_form_type: 4 | Footnotes: F2, F3, F1
• Sold 4,930 shares of Common Stock at $70.8359 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: false | shares_owned_after: 7,681.00 | transaction_form_type: 4 | Footnotes: F2, F4, F1
• Acquired 228 shares of Common Stock at $71.38 per share (Direct)
  Date: 2025-09-02 | Code: A | equity_swap_involved: false | shares_owned_after: 7,909.00 | transaction_form_type: 4 | Footnotes: F5, F6, F1
• Acquired 228 shares of Common Stock (Direct)
  Date: 2025-09-02 | Code: A | equity_swap_involved: false | shares_owned_after: 8,137.00 | transaction_form_type: 4 | Footnotes: F7, F1
• Sold 233 shares of Common Stock at $71.38 per share (Direct)
  Date: 2025-09-03 | Code: F | equity_swap_involved: false | shares_owned_after: 7,904.00 | transaction_form_type: 4 | Footnotes: F8, F9, F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-09-02 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 59,717.00 | Footnotes: F10
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-09-02 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 40,000.00 | Footnotes: F11
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-09-02 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 10,000.00 | Footnotes: F12
• Sold 20,000 shares of Stock option (right to buy) at $5.05 per share (Derivative)
  Date: 2025-09-02 | Code: M | Expires: 2026-05-02 | equity_swap_involved: false | shares_owned_after: 1,986.00 | transaction_form_type: 4 | Footnotes: F13

Footnotes:

• F1: Includes 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, and 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
• F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction.
• F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.72 to $70.715 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
• F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.72 to $71.09 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
• F5: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 2, 2025.
• F6: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
• F7: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
• F8: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
• F9: The closing price on September 2, 2025 was used to calculate the withholding obligation.
• F10: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
• F11: Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
• F12: Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
• F13: Fully exercisable.
• REMARKS: President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.